KARACHI: The local pharmaceutical company has threatened to return the privately-imported Russian COVID-19 vaccine, Sputnik V, after showing disagreement over its price recommended by the Drug Regulatory Authority of Pakistan (DRAP), ARY News reported on Wednesday.
The officials of a local pharmaceutical firm have threatened to return the Russian COVID-19 vaccines after showing disagreement to sell them at the government price, sources said. The importer said that it is impossible to supply the Russian Sputnik V vaccine at the government price.
The officials added that the importer has an option to return the vaccines over not getting a good price.
Read: Single-dose COVID-19 vaccine to arrive in Pakistan on March 25
The Drug Regulatory Authority of Pakistan (DRAP) had granted approval to the Russian vaccine for Covid-19, for emergency use in February.
Sputnik V could be administered to a person of 18 and above it. The vaccine requires to store at minus-18 Celsius temperature, according to the sources at DRAP.
Sputnik V is one of four vaccines approved for emergency use in Pakistan, in addition to those by China’s Sinopharm and CanSinoBio, and the AstraZeneca-Oxford University shot.
Read: China announces to gift more doses of COVID vaccine to Pakistan
On March 18, it emerged that a pharmaceutical company of Pakistan had received the first consignment of privately-imported Russian made Sputnik-V vaccine.
Two pharmaceutical companies are importing vaccines from abroad with one hailing from Karachi importing the Russian vaccine while the Chinese vaccine would be imported by a multi-national pharma company.
The health ministry had recommended the price of two anti-COVID jabs of the Russian vaccine be set at Rs 8,449. The packet containing four doses of Sputnik-V is set at Rs 16,560 while 10 and 20 doses would be available at Rs40,555 and Rs 81,110 respectively after approval from the federal cabinet.
The post Pharma firm shows disagreement over govt price of Russian vaccine appeared first on ARY NEWS.
from ARY NEWS https://ift.tt/2OUabtG
No comments:
Post a Comment